{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:16:55Z","timestamp":1793146615633,"version":"4.5.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,7,18]],"date-time":"2023-07-18T00:00:00Z","timestamp":1689638400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,18]],"date-time":"2023-07-18T00:00:00Z","timestamp":1689638400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Medical Science Research Project of Hebei Provincial Health Commission","award":["20200230, 20200237"],"award-info":[{"award-number":["20200230, 20200237"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>MicroRNA (miRNA) plays a critical function in the progression of acute coronary syndrome (ACS) and is associated with major adverse cardiovascular events (MACEs) after undergoing percutaneous coronary intervention (PCI). This research was designed to probe the diagnostic accuracy of miR-483-5p in patients with ACS and its predictive value of MACEs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>118 patients with ACS (40 with unstable angina pectoris [UAP] and 78 with acute myocardial infarction [AMI]) and 75 healthy controls were enrolled. Serum miR-483-5p was detected in the subjects by reverse transcription-quantitative real-time PCR (RT-qPCR). ROC curve and logistic regression models were employed to estimate the diagnosis. Patients were monitored for 6 months after PCI to document the occurrence of MACEs. Kaplan-Meier survival was conducted to explore the predictive significance of miR-483-5p for the MACEs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Serum miR-483-5p levels were higher in ACS patients and associated with SYNTAX score and Gensini score. miR-483-5p was effective in identifying ACS patients from healthy individuals (AUC\u2009=\u20090.919) and AMI patients from ACS patients (AUC\u2009=\u20090.867), demonstrating a high diagnostic value, proven by logistic regression (OR\u2009=\u20099.664, 95%CI\u2009=\u20094.462\u201320.928,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001). The prevalence of MACEs during follow-up were 24.58%, and a higher prevalence of MACEs were observed in patients with elevated miR-483-5p (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.01). miR-483-5p was also an effective predictor of MACE occurrence (HR\u2009=\u20095.955, 95%CI\u2009=\u20091.928\u201318.389,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.002).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Expression of serum miR-483-5p can be utilized as a non-invasive marker for diagnosing ACS and predicting the onset of MACE after PCI.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12872-023-03387-5","type":"journal-article","created":{"date-parts":[[2023,7,18]],"date-time":"2023-07-18T08:02:33Z","timestamp":1689667353000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Circulating mir-483-5p as a novel diagnostic biomarker for acute coronary syndrome and its predictive value for the clinical outcome after PCI"],"prefix":"10.1186","volume":"23","author":[{"given":"Yuying","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinxing","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanzhuo","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhong","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,18]]},"reference":[{"key":"3387_CR1","doi-asserted-by":"crossref","unstructured":"Shin M, Mun S, Park SH, Lee J, Kang HG. Serum biomarker discovery related to pathogenesis in acute coronary syndrome by proteomic approach. Biosci Rep 2021, 41.","DOI":"10.1042\/BSR20210344"},{"key":"3387_CR2","doi-asserted-by":"crossref","unstructured":"Shi Z, Zhao C, Hu J, Dai Q, Guan M, Zhong C, Tian G, Shang H. The application of traditional chinese medicine injection on patients with acute coronary syndrome during the perioperative period of percutaneous coronary intervention: A systematic review and meta-analysis of randomized controlled trials. Evid Based Complement Alternat Med 2020, 2020:3834128.","DOI":"10.1155\/2020\/3834128"},{"key":"3387_CR3","first-page":"7840852","volume":"2022","author":"L Liu","year":"2022","unstructured":"Liu L, Ding X, Han Y, Lv J. Effects and safety of sacubitril\/valsartan for patients with myocardial infarction: a systematic review and meta-analysis. J Healthc Eng. 2022;2022:7840852.","journal-title":"J Healthc Eng"},{"key":"3387_CR4","doi-asserted-by":"crossref","unstructured":"Wang L, Jin Y. Noncoding rnas as biomarkers for acute coronary syndrome. Biomed Res Int 2020, 2020:3298696.","DOI":"10.1155\/2020\/3298696"},{"key":"3387_CR5","doi-asserted-by":"publisher","first-page":"e048994","DOI":"10.1136\/bmjopen-2021-048994","volume":"11","author":"JQ Mol","year":"2021","unstructured":"Mol JQ, Belkacemi A, Volleberg RH, Meuwissen M, Protopopov AV, Laanmets P, Krestyaninov OV, Dennert R, Oemrawsingh RM, van Kuijk JP, et al. Identification of anatomic risk factors for acute coronary events by optical coherence tomography in patients with myocardial infarction and residual nonflow limiting lesions: Rationale and design of the pectus-obs study. BMJ Open. 2021;11:e048994.","journal-title":"BMJ Open"},{"key":"3387_CR6","doi-asserted-by":"crossref","unstructured":"Szelenberger R, Karbownik MS, Kacprzak M, Maciak K, Bijak M, Zielinska M, Czarny P, Sliwinski T, Saluk-Bijak J. Screening analysis of platelet mirna profile revealed mir-142-3p as a potential biomarker in modeling the risk of acute coronary syndrome. Cells 2021, 10.","DOI":"10.3390\/cells10123526"},{"key":"3387_CR7","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1186\/s12872-017-0653-8","volume":"17","author":"R Bai","year":"2017","unstructured":"Bai R, Yang Q, Xi R, Li L, Shi D, Chen K. Mir-941 as a promising biomarker for acute coronary syndrome. BMC Cardiovasc Disord. 2017;17:227.","journal-title":"BMC Cardiovasc Disord"},{"key":"3387_CR8","doi-asserted-by":"publisher","first-page":"5632","DOI":"10.1080\/21655979.2021.1967066","volume":"12","author":"J Yu","year":"2021","unstructured":"Yu J, Li Y, Leng D, Cao C, Yu Y, Wang Y. Microrna-3646 serves as a diagnostic marker and mediates the inflammatory response induced by acute coronary syndrome. Bioengineered. 2021;12:5632\u201340.","journal-title":"Bioengineered"},{"key":"3387_CR9","doi-asserted-by":"publisher","first-page":"8266","DOI":"10.1080\/21655979.2022.2051885","volume":"13","author":"T Chen","year":"2022","unstructured":"Chen T, Zhang X, Qian W, Zhou R, Su M, Ma Y. Serum mir-497-5p serves as a diagnostic biomarker for acute coronary syndrome and predicts the occurrence of major adverse cardiovascular events after percutaneous coronary intervention. Bioengineered. 2022;13:8266\u201376.","journal-title":"Bioengineered"},{"key":"3387_CR10","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s12872-021-01891-0","volume":"21","author":"W Zhang","year":"2021","unstructured":"Zhang W, Chang G, Cao L, Ding G. Dysregulation of serum mir-361-5p serves as a biomarker to predict disease onset and short-term prognosis in acute coronary syndrome patients. BMC Cardiovasc Disord. 2021;21:74.","journal-title":"BMC Cardiovasc Disord"},{"key":"3387_CR11","doi-asserted-by":"publisher","first-page":"48145","DOI":"10.18632\/oncotarget.18308","volume":"8","author":"S Li","year":"2017","unstructured":"Li S, Lee C, Song J, Lu C, Liu J, Cui Y, Liang H, Cao C, Zhang F, Chen H. Circulating micrornas as potential biomarkers for coronary plaque rupture. Oncotarget. 2017;8:48145\u201356.","journal-title":"Oncotarget"},{"key":"3387_CR12","doi-asserted-by":"publisher","first-page":"10548","DOI":"10.1038\/s41598-021-89981-z","volume":"11","author":"S Tian","year":"2021","unstructured":"Tian S, Cao Y, Wang J, Bi Y, Zhong J, Meng X, Sun W, Yang R, Gan L, Wang X, et al. The mir-378c-samd1 circuit promotes phenotypic modulation of vascular smooth muscle cells and foam cells formation in atherosclerosis lesions. Sci Rep. 2021;11:10548.","journal-title":"Sci Rep"},{"key":"3387_CR13","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1093\/ejcts\/ezw245","volume":"51","author":"L Harling","year":"2017","unstructured":"Harling L, Lambert J, Ashrafian H, Darzi A, Gooderham NJ, Athanasiou T. Elevated serum microrna 483-5p levels may predict patients at risk of post-operative atrial fibrillation. Eur J Cardiothorac Surg. 2017;51:73\u20138.","journal-title":"Eur J Cardiothorac Surg"},{"key":"3387_CR14","doi-asserted-by":"publisher","first-page":"2949","DOI":"10.1093\/eurheartj\/eht296","volume":"34","author":"M Task Force","year":"2013","unstructured":"Task Force M, Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden C, Budaj A, Bugiardini R, Crea F, Cuisset T, et al. 2013 esc guidelines on the management of stable coronary artery disease: the task force on the management of stable coronary artery disease of the european society of cardiology. Eur Heart J. 2013;34:2949\u20133003.","journal-title":"Eur Heart J"},{"key":"3387_CR15","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1161\/CIR.0b013e31820f2f3e","volume":"123","author":"RS Wright","year":"2011","unstructured":"Wright RS, Anderson JL, Adams CD, Bridges CR, Casey DE Jr, Ettinger SM, Fesmire FM, Ganiats TG, Jneid H, Lincoff AM, et al. 2011 accf\/aha focused update of the guidelines for the management of patients with unstable angina\/ non-st-elevation myocardial infarction (updating the 2007 guideline): a report of the american college of cardiology foundation\/american heart association task force on practice guidelines. Circulation. 2011;123:2022\u201360.","journal-title":"Circulation"},{"key":"3387_CR16","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1093\/eurheartj\/ehy856","volume":"40","author":"K Thygesen","year":"2019","unstructured":"Thygesen K. Ten commandments\u2019 for the fourth universal definition of myocardial infarction 2018. Eur Heart J. 2019;40:226.","journal-title":"Eur Heart J"},{"key":"3387_CR17","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1056\/NEJMoa0804626","volume":"360","author":"PW Serruys","year":"2009","unstructured":"Serruys PW, Morice MC, Kappetein AP, Colombo A, Holmes DR, Mack MJ, Stahle E, Feldman TE, van den Brand M, Bass EJ, et al. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med. 2009;360:961\u201372.","journal-title":"N Engl J Med"},{"key":"3387_CR18","doi-asserted-by":"publisher","first-page":"778615","DOI":"10.3389\/fcvm.2021.778615","volume":"8","author":"KY Wang","year":"2021","unstructured":"Wang KY, Zheng YY, Wu TT, Ma YT, Xie X. Predictive value of gensini score in the long-term outcomes of patients with coronary artery disease who underwent pci. Front Cardiovasc Med. 2021;8:778615.","journal-title":"Front Cardiovasc Med"},{"key":"3387_CR19","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.jjcc.2021.09.021","volume":"79","author":"R Fujiwara","year":"2022","unstructured":"Fujiwara R, Yahiro R, Horio T, Miyauchi M, Yoshimura R, Matsuoka Y, Yokouchi G, Sakamoto Y, Matsumoto N, Fukuda K, et al. Achilles tendon thickness is associated with coronary lesion severity in acute coronary syndrome patients without familial hypercholesterolemia. J Cardiol. 2022;79:311\u20137.","journal-title":"J Cardiol"},{"key":"3387_CR20","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1016\/S0140-6736(21)02391-6","volume":"399","author":"BA Bergmark","year":"2022","unstructured":"Bergmark BA, Mathenge N, Merlini PA, Lawrence-Wright MB, Giugliano RP. Acute coronary syndromes. Lancet. 2022;399:1347\u201358.","journal-title":"Lancet"},{"key":"3387_CR21","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s11739-017-1612-1","volume":"12","author":"P Garg","year":"2017","unstructured":"Garg P, Morris P, Fazlanie AL, Vijayan S, Dancso B, Dastidar AG, Plein S, Mueller C, Haaf P. Cardiac biomarkers of acute coronary syndrome: from history to high-sensitivity cardiac troponin. Intern Emerg Med. 2017;12:147\u201355.","journal-title":"Intern Emerg Med"},{"key":"3387_CR22","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.ehj.2018.04.008","volume":"70","author":"M Abd El Baky Mahmoud","year":"2018","unstructured":"Abd El Baky Mahmoud M, Shaaban MAA, Ali Ramzy A. Clinical role of serum copeptin in acute coronary syndrome. Egypt Heart J. 2018;70:155\u20139.","journal-title":"Egypt Heart J"},{"key":"3387_CR23","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1177\/2048872613514015","volume":"3","author":"T Raskovalova","year":"2014","unstructured":"Raskovalova T, Twerenbold R, Collinson PO, Keller T, Bouvaist H, Folli C, Giavarina D, Lotze U, Eggers KM, Dupuy AM, et al. Diagnostic accuracy of combined cardiac troponin and copeptin assessment for early rule-out of myocardial infarction: a systematic review and meta-analysis. Eur Heart J Acute Cardiovasc Care. 2014;3:18\u201327.","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"3387_CR24","doi-asserted-by":"publisher","first-page":"e0125430","DOI":"10.1371\/journal.pone.0125430","volume":"10","author":"X Li","year":"2015","unstructured":"Li X, Yang Y, Wang L, Qiao S, Lu X, Wu Y, Xu B, Li H, Gu D. Plasma mir-122 and mir-3149 potentially novel biomarkers for acute coronary syndrome. PLoS ONE. 2015;10:e0125430.","journal-title":"PLoS ONE"},{"key":"3387_CR25","doi-asserted-by":"crossref","unstructured":"Tong KL, Mahmood Zuhdi AS, Wan Ahmad WA, Vanhoutte PM, de Magalhaes JP, Mustafa MR, Wong PF. Circulating micrornas in young patients with acute coronary syndrome. Int J Mol Sci 2018, 19.","DOI":"10.3390\/ijms19051467"},{"key":"3387_CR26","doi-asserted-by":"publisher","first-page":"e018999","DOI":"10.1161\/JAHA.120.018999","volume":"10","author":"M Shen","year":"2021","unstructured":"Shen M, Xu X, Liu X, Wang Q, Li W, You X, Peng R, Yuan Y, Long P, Niu R, et al. Prospective study on plasma microrna-4286 and incident acute coronary syndrome. J Am Heart Assoc. 2021;10:e018999.","journal-title":"J Am Heart Assoc"},{"key":"3387_CR27","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1002\/ejhf.116","volume":"16","author":"AC Morley-Smith","year":"2014","unstructured":"Morley-Smith AC, Mills A, Jacobs S, Meyns B, Rega F, Simon AR, Pepper JR, Lyon AR, Thum T. Circulating micrornas for predicting and monitoring response to mechanical circulatory support from a left ventricular assist device. Eur J Heart Fail. 2014;16:871\u20139.","journal-title":"Eur J Heart Fail"},{"key":"3387_CR28","doi-asserted-by":"publisher","first-page":"107602962110345","DOI":"10.1177\/10760296211034579","volume":"27","author":"W Fan","year":"2021","unstructured":"Fan W, Zhang Y, Gao X, Liu Y, Shi F, Liu J, Sun L. The prognostic value of a derived neutrophil-lymphocyte ratio in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Clin Appl Thromb Hemost. 2021;27:10760296211034579.","journal-title":"Clin Appl Thromb Hemost"},{"key":"3387_CR29","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s12872-022-02976-0","volume":"23","author":"JT Luo","year":"2023","unstructured":"Luo JT, Zeng CM, Zhao YM, Zeng ZY. The relationship between homocysteine and cardiopulmonary exercise testing in patients with acute coronary syndrome after percutaneous coronary intervention. BMC Cardiovasc Disord. 2023;23:3.","journal-title":"BMC Cardiovasc Disord"},{"key":"3387_CR30","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s12944-019-0979-6","volume":"18","author":"Z Zhong","year":"2019","unstructured":"Zhong Z, Hou J, Zhang Q, Zhong W, Li B, Li C, Liu Z, Yang M, Zhao P. Assessment of the ldl-c\/hdl-c ratio as a predictor of one year clinical outcomes in patients with acute coronary syndromes after percutaneous coronary intervention and drug-eluting stent implantation. Lipids Health Dis. 2019;18:40.","journal-title":"Lipids Health Dis"},{"key":"3387_CR31","doi-asserted-by":"publisher","first-page":"e0200076","DOI":"10.1371\/journal.pone.0200076","volume":"13","author":"MM Vroegindewey","year":"2018","unstructured":"Vroegindewey MM, Schuurman AS, Oemrawsingh RM, van Geuns RJ, Kardys I, Ligthart J, Daemen J, Boersma E, Serruys PW, Akkerhuis KM. Syntax score ii predicts long-term mortality in patients with one- or two-vessel disease. PLoS ONE. 2018;13:e0200076.","journal-title":"PLoS ONE"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-023-03387-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12872-023-03387-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-023-03387-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,18]],"date-time":"2023-07-18T08:03:43Z","timestamp":1689667423000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccardiovascdisord.biomedcentral.com\/articles\/10.1186\/s12872-023-03387-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,18]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["3387"],"URL":"https:\/\/doi.org\/10.1186\/s12872-023-03387-5","relation":{},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,18]]},"assertion":[{"value":"3 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"There is no conflict of interest in this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Subjects signed an informed consent form before enrollment. With the approval of the No.980 Hospital of PLA Joint Logistics Support Force Medical Ethics Committee, this research protocol strictly adhered to the Helsinki Declaration principles.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"N\/A.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"360"}}